NHS rolls out new initiative to identify pancreatic cancer earlier
The pilot will see GP practices look at patient records to identify those most at risk
Read More
Tag: pancreatic cancer
myTomorrows and Pancreatic Cancer Europe partner on clinical trials
The partnership will improve care for patients with pancreatic cancer
Read More
Immunotherapies could target aggressive pancreatic cancer, research indicates
Scientists have discovered that hard-to-treat pancreatic cancer hijacks a key immune system response
Read More
EU nod for Lynparza in pancreatic cancer
The drug is the only PARP inhibitor approved in this disease
Read More
Lynparza backed by CHMP for BRCA-mutated pancreatic cancer
Lynparza is the only PARP inhibitor to show patient benefit in a Phase III trial in this setting, says AZ
Read More
Biodesix, Immodulon team up for pancreatic cancer treatment
The partnership will focus on the analysis of the circulating proteome of advanced pancreatic cancer patients treated with IMM-10.
Read More
Lynparza successful in pancreatic cancer trial
AstraZeneca and MSD’s Lynparza is the first PARP inhibitor to demonstrate a benefit in pancreatic cancer, having hit targets in the Phase III POLO trial.
Read More
AZ/MSD’s Lynparza assigned Orphan status in US
AstraZeneca and MSD’s PARP inhibitor Lynparza has been granted orphan drug designation in the US for the treatment of pancreatic cancer.
Read More
Pancreatic cancer survival much lower than thought, research finds
Pancreatic Cancer UK is calling for greater investment in research funding for pancreatic cancer as new data reveals that just three percent of patients with the most common form will survive beyond five years.
Read More
Liverpool Uni researchers given £1.5m for pancreatic cancer study
Scientists at the University of Liverpool have been awarded £1.5 million by Cancer Research UK for work that aims to boost understanding about pancreatic cancer.
Read More
Pancreatic cancer patients in England get CDF access to Abraxane
Patients with pancreatic cancer living in England can from today potentially get access to a new treatment option after funding for Celgene’s Abraxane was approved for NHS use.
Read More
Fast-track pancreatic cancer surgery boosts success, saves money
Accelerating access to pancreatic surgery has been shown to boost success rates by more than a fifth with a cost saving to the NHS of around £3,200 per patient.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
